Corpus Intelligence IC Memo — SPRING MOUNTAIN SAHARA 2026-04-26 10:37 UTC
IC Memo — SPRING MOUNTAIN SAHARA
Investment Committee Memorandum | NV | 30 beds | Grade C | EBITDA uplift $409K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

SPRING MOUNTAIN SAHARA

CCN 294010 | nan, NV | 30 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

SPRING MOUNTAIN SAHARA is a 30-bed suburban community hospital in nan, NV with $5.4M in net patient revenue and a 14.3% operating margin. The hospital serves a payer mix of 10.9% Medicare, 0.9% Medicaid, and 88.2% commercial.

Thesis: Turnaround. Our ML models identify $409K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 14.3% to 21.9% (+757bps).

Net Revenue HCRIS$5.4M
Current EBITDA COMPUTED$774K
Operating Margin COMPUTED14.3%
Occupancy HCRIS54.5%
Revenue / Bed COMPUTED$180K
Net-to-Gross HCRIS40.8%
Distress Probability ML48.0%

2. Market Context & Competitive Position

58
NV Hospitals
0.4%
State Median Margin
16
Comparable Hospitals

NV has 58 Medicare-certified hospitals with a median operating margin of 0.4%. The target's margin of 14.3% places it above the state median. Among 16 size-comparable peers (15-60 beds), the median margin is 4.7%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (15-60), prioritizing same-state peers. 16 hospitals in the comp set.

HospitalStateBedsRevenueMargin
SPRING MOUNTAIN SAHARA (Target)NV30$5.4M14.3%
CARSON VALLEY MEDICAL CENTERNV23$84.3M6.8%
NORTHEASTERN NEVADA REGIONAL HNV59$84.2M15.5%
BANNER CHURCHILL COMMUNITY HOSNV25$69.2M6.8%
DIGINTY HEALTH ST ROSE DOMINICNV32$61.5M12.2%
HUMBOLDT GENERAL HOSPITALNV25$58.8M-37.3%
DIGNITY HEALTH REHABILITATION NV60$41.4M12.1%
PAM REHAB HOSP OF CENTENNIAL HNV44$35.7M29.1%
WILLIAM BEE RIRIE HOSPITALNV25$35.1M-17.9%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $409K (757bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$113K+210bp18mo
Denial Rate Reduction12.0%6.5%$112K+208bp12mo
Cost to Collect4.5%2.5%$108K+200bp12mo
A/R Days Reduction5200.0%3800.0%$66K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+18bp6mo

5. EBITDA Bridge

Net Collection Rate
$113K
Denial Rate Reduction
$112K
Cost to Collect
$108K
A/R Days Reduction
$66K
Clean Claim Rate
$10K
Total EBITDA Uplift$409K
Current EBITDA$774K
+ RCM Uplift+$409K
Pro Forma EBITDA$1.2M
Current Margin14.3%
Pro Forma Margin21.9%
WC Released (1x)$207K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$1.2M$9.2M7.72x50.5%
Base (11x exit)10.0x11.0x$1.2M$10.5M8.82x54.5%
Bull Case9.0x11.0x$1.1M$12.2M11.41x62.7%
Bull (12x exit)9.0x12.0x$1.1M$13.7M12.75x66.4%
Bear Case11.0x10.0x$1.3M$6.8M5.16x38.9%
Bear (11x exit)11.0x11.0x$1.3M$7.9M6.00x43.1%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 16 hospitals with 15-60 beds
  • Same-state prioritization (n=17)
  • Comp margins: P25=-14.0% / P50=4.7% / P75=11.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.